Zymeworks (ZYME) closed out FY 2025 with Q4 revenue of US$2.5 million and a basic EPS loss of US$0.55, while net income excluding extra items was a loss of US$41.2 million, setting a cautious tone around margins and scale. Over the past four quarters, the company has seen total revenue range from US$2.5 million to US$48.7 million per quarter and basic EPS swing between a small profit of US$0.03 and a loss of US$0.55. This gives investors a wide earnings range to weigh against forecasts and margin expectations. In this context, expectations for stronger earnings and revenue growth put the spotlight on how quickly margins can move toward more sustainable levels.

See our full analysis for Zymeworks.

With the latest numbers on the table, the next step is to set these results against the prevailing narratives around Zymeworks's growth, risks, and path to profitability to see which stories hold up and which look stretched.

TTM losses of US$81 million frame the story

• Over the trailing twelve months, Zymeworks booked total revenue of US$106.0 million and a net income loss of US$81.1 million, which sits between the deeper loss of US$122.7 million a year earlier and the smaller quarterly loss of US$41.2 million in Q4 2025.
• Supporters who lean bullish point to forecast earnings growth of about 30.8% per year and an expected move to profitability within three years. That view has to be weighed against the current TTM loss of US$81.1 million and the fact that only one of the last four quarters, Q2 2025, showed a small profit of US$2.3 million.
  • The bullish narrative highlights a five year trend of losses narrowing by 18.1% per year, but the TTM figures still show negative earnings, so the improvement is not yet reflected in sustained quarterly profitability.
  • Forecast revenue growth of 10.7% per year is slightly below the broader US market forecast of 11.4%. This means the earnings ramp that bulls focus on would need to come more from margin progress than from outpacing market level top line growth.

Bulls argue that today’s TTM loss is a temporary phase before a sharper earnings ramp. Current figures still show a business that is loss making and dependent on that future shift to play out, which is explored in more depth in the 🐂 Zymeworks Bull Case

Revenue swings from US$2.5 million to US$48.7 million

• Across FY 2025, quarterly revenue moved from US$27.1 million in Q1 to US$48.7 million in Q2, then US$27.6 million in Q3 and finally US$2.5 million in Q4, illustrating how reported revenue can jump when milestone income is recognized and then fall back when it is not.
• Skeptics focus on this pattern, arguing in the bearish view that heavy reliance on milestone payments, such as the US$25.0 million pasritamig milestone inside Q3’s US$27.6 million revenue, leaves Zymeworks with lumpy top line numbers that may not translate into steady cash flows or consistent margin improvement.
  • The bearish narrative flags that only US$1.0 million of that same Q3 revenue came from recurring Ziihera royalties, which is small compared with the US$27.6 million total and highlights how concentrated revenue can be in single events.
  • With TTM revenue at US$106.0 million and a TTM net loss of US$81.1 million, bears argue that milestone driven spikes have not yet been enough to offset ongoing operating expenses and R&D spending in a durable way.

Skeptics warn that these sharp revenue swings make it harder to rely on near term results as a guide for steady earnings power, a tension that the fuller cautious case digs into in 🐻 Zymeworks Bear Case

P/S of 18.5x and DCF fair value gap

• At a share price of US$26.60 and a TTM revenue base of US$106.0 million, Zymeworks trades on a P/S of 18.5x, which is higher than the US biotechs industry average of 10.9x but below a peer group average of 35.1x, while a DCF fair value of US$46.06 and an analyst consensus price target of US$40.08 both sit above the current price.
• The consensus narrative points to this mix as a balancing act. A DCF fair value that is above the current market price and analyst expectations that earnings could eventually reach US$23.6 million if margins improve sit alongside the present TTM loss of US$81.1 million and a revenue growth forecast of 10.7% per year below the US market. This combination highlights why the stock might justifiably trade at a premium P/S, but still requires investors to accept ongoing losses while waiting for any margin shift to come through.
  • Analysts assume revenue could grow about 20.4% per year in their central case, which is faster than the 10.7% figure used in the separate growth forecast, so the valuation signals reflect a range of growth views rather than a single path.
  • The fact that Zymeworks is expected by some forecasts to remain unprofitable over the next three years, despite those higher revenue assumptions and the current premium P/S, means investors are weighing future margin recovery against current negative earnings and a relatively rich sales multiple.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Zymeworks on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of bulls, bears, and middle ground views feels mixed, use it as a prompt to move quickly and test the numbers for yourself instead of relying on headlines or sentiment alone. Then weigh those findings against the 3 key rewards

See What Else Is Out There

Zymeworks pairs a TTM loss of US$81.1 million with lumpy milestone driven revenue and a premium 18.5x P/S, which keeps overall risk elevated.

If that mix of losses, volatile revenue and valuation premium feels uncomfortable, it is worth quickly checking 72 resilient stocks with low risk scores to compare with companies screened for more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.